Medical Editor September 29, 2020 GlaxoSmithKline’s Nucala targets rival AstraZeneca with FDA nod for rare white blood cell disease – FiercePharma GlaxoSmithKline’s Nucala targets rival AstraZeneca with FDA nod for rare white blood cell disease FiercePharma